Ketamine for the Treatment of Opioid Use Disorder and Depression
Randomised, parallel-group Phase II study (n=21 actual) testing intranasal ketamine (60 mg) twice weekly for 4 weeks versus saline placebo in patients with co-occurring opioid use disorder on buprenorphine and treatment-resistant major depressive disorder.
Details
This parallel, randomised, triple-masked Phase II trial compares intranasal ketamine hydrochloride (60 mg) to saline placebo administered twice weekly for four weeks in participants on buprenorphine with opioid use disorder and comorbid treatment-resistant major depressive disorder.
Primary aims are to evaluate whether adjunctive ketamine improves treatment outcomes for opioid addiction and depressive symptoms; assessments include MADRS, OUD criteria, safety monitoring, and urine drug screens over an ~8-week participation period.